{"id":"NCT02004522","sponsor":"SecuraBio","briefTitle":"A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)","officialTitle":"A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2017-05-19","completion":"2021-06","firstPosted":"2013-12-09","resultsPosted":"2019-01-08","lastUpdate":"2023-09-21"},"enrollment":319,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":[{"type":"DRUG","name":"Duvelisib","otherNames":["Copiktra, IPI-145, PI3K Inhibitor"]},{"type":"DRUG","name":"Ofatumumab","otherNames":["Arzerra"]}],"arms":[{"label":"Duvelisib","type":"EXPERIMENTAL"},{"label":"Ofatumumab","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years","effectByArm":[{"arm":"Duvelisib","deltaMin":13.3,"sd":null},{"arm":"Ofatumumab","deltaMin":9.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":15},"locations":{"siteCount":92,"countries":["United States","Australia","Austria","Belgium","France","Germany","Hungary","Italy","New Zealand","Spain","United Kingdom"]},"refs":{"pmids":["30287523"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":124,"n":158},"commonTop":["Diarrhoea","Neutropenia","Pyrexia","Cough","Anaemia"]}}